Home Fluorides 1817630-30-0
1817630-30-0,MFCD30802158
Catalog No.:AA00230H

1817630-30-0 | (3S,4S,5S)-4-Ethyl-3-fluoro-5-(hydroxymethyl)pyrrolidin-2-one

Pack Size
Purity
Availability
Price(USD)
Quantity
  
100mg
95%
in stock  
$257.00   $180.00
- +
250mg
95%
in stock  
$387.00   $271.00
- +
500mg
95%
in stock  
$580.00   $406.00
- +
1g
95%
in stock  
$987.00   $691.00
- +
5g
95%
in stock  
$3,457.00   $2,420.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00230H
Chemical Name:
(3S,4S,5S)-4-Ethyl-3-fluoro-5-(hydroxymethyl)pyrrolidin-2-one
CAS Number:
1817630-30-0
Molecular Formula:
C7H12FNO2
Molecular Weight:
161.1741
MDL Number:
MFCD30802158
SMILES:
CC[C@H]1[C@@H](CO)NC(=O)[C@H]1F
Properties

Downstream Synthesis Route

[1]CurrentPatentAssignee:PFIZERINC-US2015/284405,2015,A1

[2]CurrentPatentAssignee:PFIZERINC-US2015/284405,2015,A1

[3]CurrentPatentAssignee:MERCKKGAA-WO2019/149522,2019,A1

[4]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-US2019/192668,2019,A1

[5]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[6]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[1]CurrentPatentAssignee:PFIZERINC-US2015/284405,2015,A1

[2]CurrentPatentAssignee:PFIZERINC-US2015/284405,2015,A1

[3]Wright,StephenW.;Li,Bryan;Peng,Zhihui;Wei,Lulin;McInturff,Emma;Place,David;Damon,DavidB.;Singer,RobertA.[OrganicProcessResearchandDevelopment,2018,vol.22,#12,p.1835-1845]

[4]Wright,StephenW.;Li,Bryan;Peng,Zhihui;Wei,Lulin;McInturff,Emma;Place,David;Damon,DavidB.;Singer,RobertA.[OrganicProcessResearchandDevelopment,2018,vol.22,#12,p.1835-1845]

[5]CurrentPatentAssignee:MERCKKGAA-WO2019/149522,2019,A1

[6]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-US2019/192668,2019,A1

[7]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[8]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[9]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[10]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[1]CurrentPatentAssignee:PFIZERINC-US2015/284405,2015,A1

[2]CurrentPatentAssignee:PFIZERINC-US2015/284405,2015,A1

[3]Wright,StephenW.;Li,Bryan;Peng,Zhihui;Wei,Lulin;McInturff,Emma;Place,David;Damon,DavidB.;Singer,RobertA.[OrganicProcessResearchandDevelopment,2018,vol.22,#12,p.1835-1845]

[4]Wright,StephenW.;Li,Bryan;Peng,Zhihui;Wei,Lulin;McInturff,Emma;Place,David;Damon,DavidB.;Singer,RobertA.[OrganicProcessResearchandDevelopment,2018,vol.22,#12,p.1835-1845]

[5]CurrentPatentAssignee:MERCKKGAA-WO2019/149522,2019,A1

[6]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-US2019/192668,2019,A1

[7]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[8]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[1]Lee,KatherineL.;Ambler,CatherineM.;Anderson,DavidR.;Boscoe,BrianP.;Bree,AndreaG.;Brodfuehrer,JoanneI.;Chang,JeanneS.;Choi,Chulho;Chung,Seungwon;Curran,KevinJ.;Day,JacquelineE.;Dehnhardt,ChristophM.;Dower,Ken;Drozda,SusanE.;Frisbie,RichardK.;Gavrin,LoriK.;Goldberg,JoelA.;Han,Seungil;Hegen,Martin;Hepworth,David;Hope,HeidiR.;Kamtekar,Satwik;Kilty,IainC.;Lee,Arthur;Lin,Lih-Ling;Lovering,FrankE.;Lowe,MichaelD.;Mathias,JohnP.;Morgan,HeidiM.;Murphy,ElizabethA.;Papaioannou,Nikolaos;Patny,Akshay;Pierce,BetsyS.;Rao,VikramR.;Saiah,Eddine;Samardjiev,IvanJ.;Samas,BrianM.;Shen,MarinaW.H.;Shin,JuliaH.;Soutter,HollyH.;Strohbach,JosephW.;Symanowicz,PeterT.;Thomason,JenniferR.;Trzupek,JohnD.;Vargas,Richard;Vincent,Fabien;Yan,Jiangli;Zapf,ChristophW.;Wright,StephenW.[JournalofMedicinalChemistry,2017,vol.60,#13,p.5521-5542]

[2]Wright,StephenW.;Li,Bryan;Peng,Zhihui;Wei,Lulin;McInturff,Emma;Place,David;Damon,DavidB.;Singer,RobertA.[OrganicProcessResearchandDevelopment,2018,vol.22,#12,p.1835-1845]

[3]Wright,StephenW.;Li,Bryan;Peng,Zhihui;Wei,Lulin;McInturff,Emma;Place,David;Damon,DavidB.;Singer,RobertA.[OrganicProcessResearchandDevelopment,2018,vol.22,#12,p.1835-1845]

[4]CurrentPatentAssignee:MERCKKGAA-WO2019/149522,2019,A1

[5]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-US2019/192668,2019,A1

[6]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[7]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1

[1]Lee,KatherineL.;Ambler,CatherineM.;Anderson,DavidR.;Boscoe,BrianP.;Bree,AndreaG.;Brodfuehrer,JoanneI.;Chang,JeanneS.;Choi,Chulho;Chung,Seungwon;Curran,KevinJ.;Day,JacquelineE.;Dehnhardt,ChristophM.;Dower,Ken;Drozda,SusanE.;Frisbie,RichardK.;Gavrin,LoriK.;Goldberg,JoelA.;Han,Seungil;Hegen,Martin;Hepworth,David;Hope,HeidiR.;Kamtekar,Satwik;Kilty,IainC.;Lee,Arthur;Lin,Lih-Ling;Lovering,FrankE.;Lowe,MichaelD.;Mathias,JohnP.;Morgan,HeidiM.;Murphy,ElizabethA.;Papaioannou,Nikolaos;Patny,Akshay;Pierce,BetsyS.;Rao,VikramR.;Saiah,Eddine;Samardjiev,IvanJ.;Samas,BrianM.;Shen,MarinaW.H.;Shin,JuliaH.;Soutter,HollyH.;Strohbach,JosephW.;Symanowicz,PeterT.;Thomason,JenniferR.;Trzupek,JohnD.;Vargas,Richard;Vincent,Fabien;Yan,Jiangli;Zapf,ChristophW.;Wright,StephenW.[JournalofMedicinalChemistry,2017,vol.60,#13,p.5521-5542]

[2]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-US2019/192668,2019,A1Locationinpatent:Paragraph2321;2328

[3]CurrentPatentAssignee:KYMERATHERAPEUTICSINC-WO2020/113233,2020,A1Locationinpatent:Paragraph00962;001001;001014-001015

[4]CurrentPatentAssignee:MERCKKGAA-WO2019/149522,2019,A1Locationinpatent:Paragraph00201;00202

[5]Wright,StephenW.;Li,Bryan;Peng,Zhihui;Wei,Lulin;McInturff,Emma;Place,David;Damon,DavidB.;Singer,RobertA.[OrganicProcessResearchandDevelopment,2018,vol.22,#12,p.1835-1845]

[6]CurrentPatentAssignee:PFIZERINC-US2015/284405,2015,A1Locationinpatent:Paragraph0850;0851

Literature
Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Building Blocks
More >
Tags:1817630-30-0 Molecular Formula|1817630-30-0 MDL|1817630-30-0 SMILES|1817630-30-0 (3S,4S,5S)-4-Ethyl-3-fluoro-5-(hydroxymethyl)pyrrolidin-2-one